Healthcare Services

Rising Autoimmune Disorders Fueling Growth in the Tildrakizumab Market

April 28, 2026April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Tildrakizumab Market From 2026 To 2030?

The tildrakizumab market has seen rapid expansion in recent years. It is projected to increase from $1.76 billion in 2025 to $1.96 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.7%. The growth observed in prior periods can be attributed to factors such as the rising prevalence of plaque psoriasis, the clinical validation of biologic efficacy, the broadening presence of specialty dermatology clinics, the increasing adoption of injectable biologics, and the availability of reimbursement assistance for biologics.

The tildrakizumab market is projected to experience substantial expansion over the coming years. By 2030, its value is anticipated to reach $3.02 billion, demonstrating a compound annual growth rate (CAGR) of 11.4%. This projected growth throughout the forecast period stems from several factors, including a heightened demand for tailored autoimmune treatments, the broadening of biologic drug applications, an increased emphasis on managing diseases over the long term, the growing acceptance of administering biologics at home, and rising financial commitments to immunology research. Key developments anticipated during this period encompass a greater utilization of specific biologic therapies, an increased uptake of il-23 inhibitors, a developing preference for injectable treatments with extended efficacy, the expansion of specialized channels for biologic distribution, and a heightened focus on treatment approaches centered around the patient.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21301&type=smp

What Major Factors Are Driving The Tildrakizumab Market Forward?

The rising prevalence of autoimmune conditions is projected to stimulate the expansion of the tildrakizumab market in the coming period. Autoimmune diseases are characterized by the immune system mistakenly attacking healthy bodily tissues. The increase in these conditions is attributed to growing environmental factors, including pollution and exposure to chemicals. Tildrakizumab functions in autoimmune diseases by inhibiting the IL-23 pathway, thereby reducing inflammation and managing symptoms. For instance, data from Public Health Scotland, a national organization based in Scotland, revealed in August 2024 that the Scottish Multiple Sclerosis Register (SMSR) recorded 455 new MS patient diagnoses in 2023. Hence, the escalating occurrence of autoimmune diseases is fueling the growth of the tildrakizumab market.

Which Segment Types Are Examined In The Tildrakizumab Market Segment Study?

The tildrakizumab market covered in this report is segmented –

1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Other Indications

2) By Dosage Form: Injectable, Oral

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End-User: Hospitals, Specialty Clinics, Homecare

Subsegments:

1) By Plaque Psoriasis: Moderate Plaque Psoriasis, Severe Plaque Psoriasis, Treatment-Resistant Plaque Psoriasis

2) By Psoriatic Arthritis: Peripheral Psoriatic Arthritis, Axial Psoriatic Arthritis, Enthesitis-related Psoriatic Arthritis

3) By Other Indications: Inflammatory Skin Disorders, Off-Label Autoimmune Conditions, Emerging Therapeutic Applications

Which Trends Are Impacting The Progress Of The Tildrakizumab Market?

Leading firms within the tildrakizumab market are prioritizing the creation of advanced formulations, like monoclonal antibody injections, to boost treatment effectiveness and better patient results. A monoclonal antibody injection involves delivering antibodies created in a lab, engineered to home in on particular antigens within the body for either treatment or prevention. As an example, in May 2023, the Indian pharmaceutical company, Sun Pharmaceutical Industries Ltd., secured approval from China’s National Medical Products Administration (NMPA) for its tildrakizumab injection, intended for managing plaque psoriasis. This treatment operates by targeting interleukin-23 (IL-23), a cytokine implicated in the inflammatory reactions leading to psoriasis. By addressing IL-23, tildrakizumab aids in decreasing inflammation and slowing down the rapid proliferation of skin cells, thereby alleviating symptoms like redness, scaling, and the development of plaques.

Which Players Are Part Of The Competitive Landscape Of The Tildrakizumab Market?

Major companies operating in the tildrakizumab market are Almirall S.A., Sun Pharmaceutical Industries Ltd., Novartis, Pfizer, Eli Lilly, Bristol Myers Squibb, Roche, Merck & Co, Janssen Biotech (Johnson & Johnson), Amgen, GSK, AbbVie, Sanofi, AstraZeneca, Innovent Biologics, Boehringer Ingelheim, LEO Pharma, Kyowa Kirin, Takeda Pharmaceutical, Regeneron Pharmaceuticals, Biocon Ltd.

Get The Full Tildrakizumab Market Report:

https://www.thebusinessresearchcompany.com/report/tildrakizumab-global-market-report

Which Region Accounts For The Largest Portion Of The Tildrakizumab Market?

North America was the largest region in the tildrakizumab market in 2025. Asia-Pacific expected to be the fastest-growing region in the forecast period. The regions covered in the tildrakizumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Tildrakizumab Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/tildrakizumab-global-market-report

Browse Through More Reports Similar to the Global Tildrakizumab Market 2026, By The Business Research Company

Fishmeal Market Report 2026

https://www.thebusinessresearchcompany.com/report/fishmeal-global-market-report

Sukuk Market Report

https://www.thebusinessresearchcompany.com/report/sukuk-global-market-report

Dulaglutide Market Report

https://www.thebusinessresearchcompany.com/report/dulaglutide-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795